Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon.
Zhang W, Vadlakonda S, Wu M, Chintareddy V, Vogeti LN, Juarez L, Muppa S, Parker C, Kellogg-Yelder D, Williams J, Polach K, Chen X, Raman K, Babu YS, Kotian P.
Zhang W, et al. Among authors: parker c.
Bioorg Med Chem. 2022 Nov 1;73:117035. doi: 10.1016/j.bmc.2022.117035. Epub 2022 Sep 30.
Bioorg Med Chem. 2022.
PMID: 36208543